. 2016 Aug 10;6:31058. doi: 10.1038/srep31058

Table 3. Characterization of cardiac function and morphology.

Exposure	STAGE	Group	Edema area, %	BPM⁴	SV, %	VFS, % SV incl.	VFS, % SV excl.	AFS, %	VL % of control	VA % of control	VC % of control	% A/V block
Transient exposure	24 h, 2 dph (13 dpe)	Control	8 ± 5^a	57 ± 6	0	18 ± 4^a	18 ± 4^a	—	—	—	—	0
		Low dose	9 ± 5^a	57 ± 7	0	16 ± 5^a	16 ± 5^a	—	—	—	—	0
		Pulse dose	10 ± 7^a	57 ± 5	0	16 ± 5^a	16 ± 5^a	—	—	—	—	0
		High dose	7 ± 4^a	56 ± 5	20	9 ± 5^b	12 ± 5^b	—	—	—	—	0
	48 h, 2 dph (12 dpe)	Control	10 ± 5^a	57 ± 8	0	17 ± 4^a	17 ± 4^a	—	—	—	—	0
		Low dose	11 ± 7^a	59 ± 7	17	13 ± 8^a,b	16 ± 6^a,b	—	—	—	—	0
		Pulse dose	9 ± 4^a	56 ± 5	7	14 ± 6^a	16 ± 5^a,b	—	—	—	—	0
		High dose	17 ± 12^b	54 ± 5	23	9 ± 7^b	13 ± 6^b	—	—	—	—	0
Continuous embryonic exposure	9 dpf	Control	†10 ± 12^a	26 ± 3^a	2 ± 4^a	—	—	—	—	—	—	—
		Low dose	†28 ± 18^b	25 ± 5^a	14 ± 5^b	—	—	—	—	—	—	—
		Pulse dose	†43 ± 32^c	26 ± 4^a	44 ± 21^c	—	—	—	—	—	—	—
		High dose	†70 ± 20^d	20 ± 6^b	49 ± 15^c	—	—	—	—	—	—	—
	0 dph (3 dpe)	Control	7 ± 6^a	41 ± 6^a	5 ± 5^a	17 ± 7^a	18 ± 6^a	25 ± 6^a	100 ± 21^a	100 ± 32^a	100 ± 5^a	0
		Low dose	16 ± 9^b	42 ± 6^a	13 ± 8^b	15 ± 7^a,b	16 ± 6^a	25 ± 7^a	89 ± 20^b	84 ± 33^b	99 ± 4^a	0
		Pulse dose	31 ± 14^c	41 ± 7^a	30 ± 15^c	12 ± 9^b	15 ± 7^a	24 ± 6^a	64 ± 16^c	49 ± 21^c	93 ± 6^b	0
		High dose	31 ± 12^c	34 ± 11^b	54 ± 28^d	4 ± 6^c	9 ± 6^b*	16 ± 8^b	51 ± 21^d	35 ± 23^d	85 ± 14^c	0
	3 dph (6 dpe)	Control	—	59 ± 7^a	2 ± 3^a	17 ± 6^a	17 ± 5^a	21 ± 7^a	—	—	—	0
		Low dose	—	59 ± 6^a	57 ± 25^b	7 ± 7^b,d	12 ± 6^b	17 ± 7^b	—	—	—	0
		Pulse dose	—	58 ± 8^a	29 ± 17^c	12 ± 8^c	15 ± 6^a,c	17 ± 6^b	—	—	—	0
		High dose	—	46 ± 10^b	72 ± 20^d	3 ± 6^d	14 ± 4^b,c*	11 ± 7^c	—	—	—	0
Larval exposure	2 dph	Control	—	73 ± 10^a	0	16 ± 4^a	—	—	—	—	—	4 ± 8^a
		Low dose	—	77 ± 7^a	0	15 ± 5^a	—	—	—	—	—	2 ± 4^a
		Pulse dose	—	78 ± 10^a	0	16 ± 5^a	—	—	—	—	—	2 ± 4^a
		High dose	—	77 ± 11^a	0	16 ± 6^a	—	—	—	—	—	2 ± 4^a
	9 dph	Control	9 ± 3^a	105 ± 12^a	0	17 ± 3^a	—	—	—	—	—	0 ± 0^a
		Low dose	12 ± 4^b	104 ±19^a	0	17 ± 4^a	—	—	—	—	—	2 ± 4^a
		Pulse dose	12 ± 4^b	110 ± 13^a	0	17 ± 4^a	—	—	—	—	—	8 ± 7^b
		High dose	13 ± 4^b	106 ± 15^a	0	21 ± 4^b	—	—	—	—	—	17 ± 12^c
	18 dph	Control	7 ± 5^a	—	—	—	—	—	—	—	—	—
		Low dose	15 ± 16^a	—	—	—	—	—	—	—	—	—
		Pulse dose	13 ± 11^a	—	—	—	—	—	—	—	—	—
		High dose	32 ± 13^b	—	—	—	—	—	—	—	—	—

⁴BPM, beats per minute; SV, silent ventricle; VFS, ventriclular fractional shortening; AFS, atrial fractional shortening; VL, ventricular length; VA, ventricular area; VC, ventricular circularity; A/V atrioventricular. Dpe = days post exposure stop.

^a–dLetters indicate significant differences between groups (p = <0.05) (groups with same letters are not significantly different from each other).

VFS measurements were not performed in animals with severely underdeveloped ventricles.

^†Incidence of edema, not area.

*Few animals with beating ventricles.